IRTC Stock Analysis: iRhythm Technologies | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 3.766m USD | 12M Return: -14.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 61.8M
Qual. Beats: 1
Rev. Trend: 99.7%
Qual. Beats: 6
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
iRhythm Holdings, Inc. (NASDAQ: IRTC) is a U.S.-based digital healthcare company focused on device-based ambulatory cardiac monitoring services used to diagnose arrhythmias. Headquartered in San Francisco and founded in 2006, the company sells the Zio family of prescription-only remote ECG monitoring products, including the Zio Monitor, Zio XT, and Zio AT systems, each featuring a patch-based monitor capable of continuously recording cardiac electrical signals for up to 14 days. Its service offering is supported by the Zio ECG Utilization Software System, which captures and analyzes patient ECG data, creating an integrated hardware-plus-software business model.
The company operates in the Health Care Equipment sub-industry and went public in October 2016, with its market cap currently in the mid-cap range. In addition to its core arrhythmia monitoring franchise, iRhythm holds a development collaboration agreement with BioIS to incorporate pulse oximetry, accelerometry, and non-invasive blood pressure technologies into future ambulatory cardiac products. The company was previously known as iRhythm Technologies, Inc. before adopting its current name in January 2026.
- Zio volume growth drives double-digit revenue gains
- CMS reimbursement decisions impact Zio service pricing
- Gross margin expansion supports path to profitability
| Net Income: -27.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 7.40 > 1.0 |
| NWC/Revenue: 69.66% < 20% (prev 84.82%; Δ -15.16% < -1%) |
| CFO/TA 0.06 > 3% & CFO 62.6m > Net Income -27.8m |
| Net Debt (258.6m) to EBITDA (12.6m): 20.53 < 3 |
| Current Ratio: 5.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.5m) vs 12m ago 2.90% < -2% |
| Gross Margin: 71.00% > 18% (prev 69.39%; Δ 1.61% > 0.5%) |
| Asset Turnover: 81.54% > 50% (prev 66.79%; Δ 14.74% > 0%) |
| Interest Coverage Ratio: -1.05 > 6 (EBIT TTM -13.8m / Interest Expense TTM 13.2m) |
| A: 0.55 (Total Current Assets 680.6m - Total Current Liabilities 131.8m) / Total Assets 1.01b |
| B: -0.81 (Retained Earnings -817.4m / Total Assets 1.01b) |
| C: -0.01 (EBIT TTM -13.8m / Avg Total Assets 966.2m) |
| D: 0.19 (Book Value of Equity 161.2m / Total Liabilities 845.2m) |
| Altman-Z'' = 1.03 = BB |
| DSRI: 0.79 (Receivables 80.9m/80.6m, Revenue 787.9m/618.6m) |
| GMI: 0.98 (GM 69.39% / 71.00%) |
| AQI: 1.05 (AQ_t 0.13 / AQ_t-1 0.12) |
| SGI: 1.27 (Revenue 787.9m / 618.6m) |
| TATA: -0.09 (NI -27.8m - CFO 62.6m) / TA 1.01b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 02, 2026, the stock is trading at USD 124.53 with a total of 624,464 shares traded. Over the past week, the price has changed by +10.72%, over one month by +14.07%, over three months by +5.34% and over the past year by -14.68%.
Current recommended Stop Loss: 116.80 (which is 6.2% or 1.3 ATR below the current price).
iRhythm Technologies has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy IRTC.
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 178.9 | 43.7% |
P/E Forward = 833.3333
P/S = 4.7799
P/B = 22.9248
Revenue TTM = 787.9m USD
EBIT TTM = -13.8m USD
EBITDA TTM = 12.6m USD
Long Term Debt = 650.3m USD (from longTermDebt, last quarter)
Short Term Debt = 16.8m USD (from shortTermDebt, last quarter)
Debt = 808.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 79.0m
Net Debt = 258.6m USD (calculated: Debt 808.3m - CCE 549.6m)
Enterprise Value = 4.02b USD (3.77b + Debt 808.3m - CCE 549.6m)
Interest Coverage Ratio = -1.05 (Ebit TTM -13.8m / Interest Expense TTM 13.2m)
EV/FCF = 109.0x (Enterprise Value 4.02b / FCF TTM 36.9m)
FCF Yield = 0.92% (FCF TTM 36.9m / Enterprise Value 4.02b)
FCF Margin = 4.69% (FCF TTM 36.9m / Revenue TTM 787.9m)
Net Margin = -3.53% (Net Income TTM -27.8m / Revenue TTM 787.9m)
Gross Margin = 71.00% ((Revenue TTM 787.9m - Cost of Revenue TTM 228.5m) / Revenue TTM)
Gross Margin QoQ = 70.89% (prev 70.88%)
Tobins Q-Ratio = 4.00 (Enterprise Value 4.02b / Total Assets 1.01b)
Interest Expense / Debt = 1.63% (Interest Expense 13.2m / Debt 808.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -10.9m (EBIT -13.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.85 (Total Current Assets 680.6m / Total Current Liabilities 140.3m)
Debt / Equity = 5.01 (Debt 808.3m / totalStockholderEquity, last quarter 161.2m)
Debt / EBITDA = 20.53 (Net Debt 258.6m / EBITDA 12.6m)
Debt / FCF = 7.00 (Net Debt 258.6m / FCF TTM 36.9m)
Total Stockholder Equity = 134.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.88% (Net Income -27.8m / Total Assets 1.01b)
RoE = -20.60% (Net Income TTM -27.8m / Total Stockholder Equity 134.9m)
RoCE = -1.76% (EBIT -13.8m / Capital Employed (Equity 134.9m + L.T.Debt 650.3m))
RoIC = -1.28% (negative operating profit) (NOPAT -10.9m / Invested Capital 852.0m)
WACC = 7.93% (E(3.77b)/V(4.57b) * Re(9.35%) + D(808.3m)/V(4.57b) * Rd(1.63%) * (1-Tc(0.21)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 2.57%
[DCF] Terminal Value 75.44% ; FCFF base≈36.9m ; Y1≈37.1m ; Y5≈39.3m
[DCF] Fair Price = 10.72 (EV 610.9m - Net Debt 258.6m = Equity 352.3m / Shares 32.9m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.87 | # QB: 1
Revenue Correlation: 99.66 | Revenue CAGR: 22.36% | SUE: 1.40 | # QB: 6
EPS current Quarter (2026-09-30): EPS=0.09 | Chg30d=+0.00% | Revisions=N/A | Analysts=10
EPS current Year (2026-12-31): EPS=0.12 | Chg30d=-8.61% | Revisions=-20% | GrowthEPS=+111.3% | GrowthRev=+17.9%
EPS next Year (2027-12-31): EPS=1.05 | Chg30d=+0.77% | Revisions=+57% | GrowthEPS=+800.2% | GrowthRev=+15.7%
[Analyst] Revisions Ratio: +57%